• Investing
  • Stock
  • Editor’s Pick
  • Economy
The Significant Deals – Economy, Investing, Stock News
Economy

American Health Care Consumers Should Have Access to Drugs and Devices Benefitting People in Developed Countries

by December 3, 2022
written by December 3, 2022
Reprinted from the Cato Institute

Swiss Medtech, a trade association representing the medical technology industry, issued a press release on November 28 praising the Swiss Parliament for enacting legislation allowing Swiss health care providers and patients to access medical devices approved by the U.S. Food and Drug Administration. Until now, the Swiss government only permitted patients and doctors to access devices that have a CE Marking, which indicates the device meets European Union standards, and the E.U. approves it for marketing among member states. The Swiss Parliament’s action should expand access and increase price competition for medical devices.

Australia began permitting patients and doctors to access FDA‐​approved medical devices in 2018 and has been allowing them to use E.U.-approved devices for several years. Israel allows devices approved in the U.S., E.U., Australia, and Canada.

U.S. lawmakers have proposed legislation permitting American health care consumers and providers to access drugs and/​or devices approved in other developed countries. Policymakers inaptly refer to the proposal as “reciprocity,” but the reform is not contingent upon the other countries permitting their residents to use FDA‐​approved drugs or devices in return.

In testimony before the Joint Economic Committee in September 2020, I stated:

Congress should pass legislation giving reciprocal approval to drugs and medical devices (which includes tests) in similar countries. Reciprocal approval already exists among the European Union states plus Iceland, Liechtenstein, and Norway. In July 2019 Senator Ted Cruz (R‑TX) introduced S.2161, the Reciprocity Ensures Streamlined Use of Lifesaving Treatment (RESULT) Act, which would allow for the marketing of drugs approved in certain countries, but not yet approved by the FDA, if “there is an unmet need.” While this is indeed a step in the right direction, in the interest of promoting competition and consumer choice, reciprocal approval should not be contingent on an unmet need.

In Drug Reformation, published later that year, Michael F. Cannon and I wrote:

…at a minimum Congress should eliminate the FDA’s ability to restrict truthful speech by manufacturers about their products and allow American consumers to purchase drugs that have won approval from designated certification agencies, including foreign regulatory bodies. According to one study, recognizing drug approvals by regulatory bodies in Canada and Europe between 2000 and 2010 would have given U.S. consumers quicker access to 37 “novel” drugs for which “no other FDA‐​approved prescription medicine had the same mechanism of action,” including 10 drugs treating mostly orphan diseases “for which no alternative therapy was available in the USA.” Such recognition would have allowed U.S. consumers to access those drugs a median of 13.6 months earlier.

If members of the incoming Congress are serious about increasing access to health care and reducing health care costs, they should, at a minimum, pass a law that allows for drug and device “reciprocity” with other developed nations.

0 comment
0
FacebookTwitterPinterestEmail

previous post
Ford is now the second best-selling EV maker in the United States
next post
Professors Are Not “Priests of Democracy”

You may also like

Government Siphon Targets Corporate Stock Buybacks

February 8, 2023

Is the Debt Ceiling Lunacy?

February 8, 2023

Book Review: How the “Chip War” Vindicates Economics

February 7, 2023

Be Grateful that First Responders and Teachers Earn...

February 7, 2023

The Not-So-Great Depression Diet

February 6, 2023

The Age of Decline

February 6, 2023

1619 Project: A Flawed Interpretation With a Hidden...

February 5, 2023

Words, Numbers, and Samuel Gregg

February 4, 2023

The Tragedy of the Monetary Commons

February 4, 2023

Supply Constraints and Inflation, Revisited

February 3, 2023
Enter Your Information Below To Receive Free Trading Ideas, Latest News, And Articles.


Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

Recent Posts

  • Ex-Coinbase manager pleads guilty to insider trading charges

    February 8, 2023
  • U.K. CMA issues provisional decision on Microsoft-Activision deal

    February 8, 2023
  • Nasdaq 100 forecast – can index continue to soar?

    February 8, 2023
  • Google stock loses 9.0% after it’s A.I event: buy the dip?

    February 8, 2023

Categories

  • Economy (1,643)
  • Editor's Pick (585)
  • Investing (4,692)
  • Stock (10)
About Us Terms & Conditions Privacy Policy Email WhiteListing Contact Us

Disclaimer: Thesignificantdeals.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2023 Thesignificantdeals.com All Rights Reserved.

The Significant Deals – Economy, Investing, Stock News
  • Investing
  • Stock
  • Editor’s Pick
  • Economy